Diane Van Hoorick

USPTO Granted Patents = 12 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 30(Granted Patents)

Company Filing History:

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371496 - T cell recruiting polypeptides based on CD3 reactivity (2025-07-29),

2. 12221487 - Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2025-02-11),

3. 11932702 - Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor (2024-03-19),

4. 11840569 - T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta (2023-12-12),

5. 11384151 - CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2022-07-12),

6. 11149086 - KV1.3 binding immunoglobulins (2021-10-19),

7. 11046767 - T cell recruiting polypeptides based on CD3 reactivity (2021-06-29),

8. 10927186 - T cell recruiting polypeptides based on TCR alpha/beta reactivity (2021-02-23),

9. 10385134 - CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2019-08-20),

10. 9783612 - CX3CR1-binding polypeptides (2017-10-10),

11. 9458235 - Method for treating a CX3CR1-associated disease with CX3CR1-binding polypeptides (2016-10-04),

12. 9035029 - CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2015-05-19),

Title: Inventor Spotlight: Diane Van Hoorick

Introduction:

Diane Van Hoorick is a brilliant inventor hailing from Laarne, Belgium, with an impressive track record of 10 patents to her name. Her innovative work in the field of biotechnology and cancer research has garnered significant attention in the scientific community.

Latest Patents:

1. Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor: Van Hoorick's groundbreaking technology provides a novel drug for cancer treatment, utilizing polypeptides with immunoglobulin single variable domains. This innovation targets glypican-3 and T cell receptors, offering new possibilities for cancer therapy.

2. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta: Her invention includes polypeptides that bind CD123 on target cells and the constant domain of TCR on T cells. These polypeptides have applications in treating CD123 associated cancers and inflammatory conditions, showcasing Van Hoorick's commitment to advancing medical treatments.

Career Highlights:

Throughout her career, Diane Van Hoorick has made significant contributions to the field of biotechnology. She has worked with reputable companies such as Ablynx N.V. and Boehringer Ingelheim International GmbH, where her innovative spirit and dedication to scientific advancement have shone through.

Collaborations:

Van Hoorick has collaborated with esteemed colleagues Alisa K Waterman and Erik Depla, pooling their expertise to drive forward cutting-edge research and development in the field of cancer treatment. Together, they have made great strides in developing novel therapies that hold promise for improving patient outcomes.

Conclusion:

Diane Van Hoorick's inventive prowess and dedication to advancing medical science make her a standout figure in the world of innovation. Her latest patents underscore her commitment to finding novel solutions for challenging medical conditions, particularly in the realm of cancer treatment. With a strong track record of patents and collaborations with top experts in the field, Van Hoorick continues to make significant contributions to the scientific community and the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.